Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis

• NASDAQ: $ACRS
• Notified: $1.85
• 16:01 EDT